BLAINTRATRACHEALSUSPENSION
Approved
Nov 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
5/8 — Partial
CUROSURF (poractant alfa) by Chiesi is surfactant activity [moa]. Approved for respiratory distress syndrome, newborn. First approved in 1999.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CUROSURF (poractant alfa) is an intratracheal surfactant suspension that restores lung compliance and gas exchange in neonates and adults with respiratory distress syndrome. It works by reducing surface tension in the alveoli, allowing collapsed lung tissue to re-expand and improving oxygenation. The drug is a natural, porcine-derived surfactant administered directly into the trachea.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team rightsizing and transition to generic defense strategies.
Mechanism of Action
Surfactant Activity
Pharmacologic Class:
Surfactant
Indications (1)
Clinical Trials (7)
A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration
Started May 2021
33 enrolled
Respiratory Distress Syndrome (RDS)
Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)
Started Jan 2021
22 enrolled
Acute Respiratory Distress Syndrome
Efficacy and Safety of Curosurf® in Patients Invasively Ventilated for Severe Bronchiolitis Under 12 Months of Age
Started Jan 2019
9 enrolled
Bronchiolitis, Viral
A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS)
Started Aug 2017
166 enrolled
Neonatal Respiratory Distress Syndrome
A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)
Started Jan 2016
123 enrolled
Respiratory Distress Syndrome, Newborn
Worked on CUROSURF at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.